AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B
1 Division of Cardiology, School of Medicine, Université Catholique de Louvain; and 2 Hormone and Metabolic Research Unit, Université Catholique de Louvain and Christian de Duve Institute of Cellular Pathology, Brussels, Belgium Submitted 1 December 2005 ; accepted in final form 10 February 2006 Dia...
Saved in:
Published in | American journal of physiology. Heart and circulatory physiology Vol. 291; no. 1; pp. H239 - H250 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.07.2006
|
Subjects | |
Online Access | Get full text |
ISSN | 0363-6135 1522-1539 |
DOI | 10.1152/ajpheart.01269.2005 |
Cover
Abstract | 1 Division of Cardiology, School of Medicine, Université Catholique de Louvain; and 2 Hormone and Metabolic Research Unit, Université Catholique de Louvain and Christian de Duve Institute of Cellular Pathology, Brussels, Belgium
Submitted 1 December 2005
; accepted in final form 10 February 2006
Diabetic hearts are known to be more susceptible to ischemic disease. Biguanides, like metformin, are known antidiabetic drugs that lower blood glucose concentrations by decreasing hepatic glucose production and increasing glucose disposal in muscle. Part of these metabolic effects is thought to be mediated by the activation of AMP-activated protein kinase (AMPK). In this work, we studied the relationship between AMPK activation and glucose uptake stimulation by biguanides and oligomycin, another AMPK activator, in both insulin-sensitive and insulin-resistant cardiomyocytes. In insulin-sensitive cardiomyocytes, insulin, biguanides and oligomycin were able to stimulate glucose uptake with the same efficiency. Stimulation of glucose uptake by insulin or biguanides was correlated to protein kinase B (PKB) or AMPK activation, respectively, and were additive. In insulin-resistant cardiomyocytes, where insulin stimulation of glucose uptake was greatly reduced, biguanides or oligomycin, in the absence of insulin, induced a higher stimulation of glucose uptake than that obtained in insulin-sensitive cells. This stimulation was correlated with the activation of both AMPK and PKB and was sensitive to the phosphatidylinositol-3-kinase/PKB pathway inhibitors. Finally, an adenoviral-mediated expression of a constitutively active form of AMPK increased both PKB phosphorylation and glucose uptake in insulin-resistant cardiomyocytes. We concluded that AMPK activators, like biguanides and oligomycin, are able to restore glucose uptake stimulation, in the absence of insulin, in insulin-resistant cardiomyocytes via the additive activation of AMPK and PKB. Our results suggest that AMPK activation could restore normal glucose metabolism in diabetic hearts and could be a potential therapeutic approach to treat insulin resistance.
diabetes; AMP-activated protein kinase; metformin; oligomycin
Address for reprint requests and other correspondence: L. Bertrand, Div. of Cardiology, Université Catholique de Louvain, Ave. Hippocrate, 55, CARD5550, B-1200 Brussels, Belgium (e-mail: bertrand{at}card.ucl.ac.be ) |
---|---|
AbstractList | Diabetic hearts are known to be more susceptible to ischemic disease. Biguanides, like metformin, are known antidiabetic drugs that lower blood glucose concentrations by decreasing hepatic glucose production and increasing glucose disposal in muscle. Part of these metabolic effects is thought to be mediated by the activation of AMP-activated protein kinase (AMPK). In this work, we studied the relationship between AMPK activation and glucose uptake stimulation by biguanides and oligomycin, another AMPK activator, in both insulin-sensitive and insulin-resistant cardiomyocytes. In insulin-sensitive cardiomyocytes, insulin, biguanides and oligomycin were able to stimulate glucose uptake with the same efficiency. Stimulation of glucose uptake by insulin or biguanides was correlated to protein kinase B (PKB) or AMPK activation, respectively, and were additive. In insulin-resistant cardiomyocytes, where insulin stimulation of glucose uptake was greatly reduced, biguanides or oligomycin, in the absence of insulin, induced a higher stimulation of glucose uptake than that obtained in insulin-sensitive cells. This stimulation was correlated with the activation of both AMPK and PKB and was sensitive to the phosphatidylinositol-3-kinase/PKB pathway inhibitors. Finally, an adenoviral-mediated expression of a constitutively active form of AMPK increased both PKB phosphorylation and glucose uptake in insulin-resistant cardiomyocytes. We concluded that AMPK activators, like biguanides and oligomycin, are able to restore glucose uptake stimulation, in the absence of insulin, in insulin-resistant cardiomyocytes via the additive activation of AMPK and PKB. Our results suggest that AMPK activation could restore normal glucose metabolism in diabetic hearts and could be a potential therapeutic approach to treat insulin resistance. 1 Division of Cardiology, School of Medicine, Université Catholique de Louvain; and 2 Hormone and Metabolic Research Unit, Université Catholique de Louvain and Christian de Duve Institute of Cellular Pathology, Brussels, Belgium Submitted 1 December 2005 ; accepted in final form 10 February 2006 Diabetic hearts are known to be more susceptible to ischemic disease. Biguanides, like metformin, are known antidiabetic drugs that lower blood glucose concentrations by decreasing hepatic glucose production and increasing glucose disposal in muscle. Part of these metabolic effects is thought to be mediated by the activation of AMP-activated protein kinase (AMPK). In this work, we studied the relationship between AMPK activation and glucose uptake stimulation by biguanides and oligomycin, another AMPK activator, in both insulin-sensitive and insulin-resistant cardiomyocytes. In insulin-sensitive cardiomyocytes, insulin, biguanides and oligomycin were able to stimulate glucose uptake with the same efficiency. Stimulation of glucose uptake by insulin or biguanides was correlated to protein kinase B (PKB) or AMPK activation, respectively, and were additive. In insulin-resistant cardiomyocytes, where insulin stimulation of glucose uptake was greatly reduced, biguanides or oligomycin, in the absence of insulin, induced a higher stimulation of glucose uptake than that obtained in insulin-sensitive cells. This stimulation was correlated with the activation of both AMPK and PKB and was sensitive to the phosphatidylinositol-3-kinase/PKB pathway inhibitors. Finally, an adenoviral-mediated expression of a constitutively active form of AMPK increased both PKB phosphorylation and glucose uptake in insulin-resistant cardiomyocytes. We concluded that AMPK activators, like biguanides and oligomycin, are able to restore glucose uptake stimulation, in the absence of insulin, in insulin-resistant cardiomyocytes via the additive activation of AMPK and PKB. Our results suggest that AMPK activation could restore normal glucose metabolism in diabetic hearts and could be a potential therapeutic approach to treat insulin resistance. diabetes; AMP-activated protein kinase; metformin; oligomycin Address for reprint requests and other correspondence: L. Bertrand, Div. of Cardiology, Université Catholique de Louvain, Ave. Hippocrate, 55, CARD5550, B-1200 Brussels, Belgium (e-mail: bertrand{at}card.ucl.ac.be ) Diabetic hearts are known to be more susceptible to ischemic disease. Biguanides, like metformin, are known antidiabetic drugs that lower blood glucose concentrations by decreasing hepatic glucose production and increasing glucose disposal in muscle. Part of these metabolic effects is thought to be mediated by the activation of AMP-activated protein kinase (AMPK). In this work, we studied the relationship between AMPK activation and glucose uptake stimulation by biguanides and oligomycin, another AMPK activator, in both insulin-sensitive and insulin-resistant cardiomyocytes. In insulin-sensitive cardiomyocytes, insulin, biguanides and oligomycin were able to stimulate glucose uptake with the same efficiency. Stimulation of glucose uptake by insulin or biguanides was correlated to protein kinase B (PKB) or AMPK activation, respectively, and were additive. In insulin-resistant cardiomyocytes, where insulin stimulation of glucose uptake was greatly reduced, biguanides or oligomycin, in the absence of insulin, induced a higher stimulation of glucose uptake than that obtained in insulin-sensitive cells. This stimulation was correlated with the activation of both AMPK and PKB and was sensitive to the phosphatidylinositol-3-kinase/PKB pathway inhibitors. Finally, an adenoviral-mediated expression of a constitutively active form of AMPK increased both PKB phosphorylation and glucose uptake in insulin-resistant cardiomyocytes. We concluded that AMPK activators, like biguanides and oligomycin, are able to restore glucose uptake stimulation, in the absence of insulin, in insulin-resistant cardiomyocytes via the additive activation of AMPK and PKB. Our results suggest that AMPK activation could restore normal glucose metabolism in diabetic hearts and could be a potential therapeutic approach to treat insulin resistance.Diabetic hearts are known to be more susceptible to ischemic disease. Biguanides, like metformin, are known antidiabetic drugs that lower blood glucose concentrations by decreasing hepatic glucose production and increasing glucose disposal in muscle. Part of these metabolic effects is thought to be mediated by the activation of AMP-activated protein kinase (AMPK). In this work, we studied the relationship between AMPK activation and glucose uptake stimulation by biguanides and oligomycin, another AMPK activator, in both insulin-sensitive and insulin-resistant cardiomyocytes. In insulin-sensitive cardiomyocytes, insulin, biguanides and oligomycin were able to stimulate glucose uptake with the same efficiency. Stimulation of glucose uptake by insulin or biguanides was correlated to protein kinase B (PKB) or AMPK activation, respectively, and were additive. In insulin-resistant cardiomyocytes, where insulin stimulation of glucose uptake was greatly reduced, biguanides or oligomycin, in the absence of insulin, induced a higher stimulation of glucose uptake than that obtained in insulin-sensitive cells. This stimulation was correlated with the activation of both AMPK and PKB and was sensitive to the phosphatidylinositol-3-kinase/PKB pathway inhibitors. Finally, an adenoviral-mediated expression of a constitutively active form of AMPK increased both PKB phosphorylation and glucose uptake in insulin-resistant cardiomyocytes. We concluded that AMPK activators, like biguanides and oligomycin, are able to restore glucose uptake stimulation, in the absence of insulin, in insulin-resistant cardiomyocytes via the additive activation of AMPK and PKB. Our results suggest that AMPK activation could restore normal glucose metabolism in diabetic hearts and could be a potential therapeutic approach to treat insulin resistance. |
Author | Hue, Louis Hebert, Alexandre D Bertrand, Luc Vanoverschelde, Jean-Louis Ginion, Audrey Beauloye, Christophe Guigas, Bruno |
Author_xml | – sequence: 1 fullname: Bertrand, Luc – sequence: 2 fullname: Ginion, Audrey – sequence: 3 fullname: Beauloye, Christophe – sequence: 4 fullname: Hebert, Alexandre D – sequence: 5 fullname: Guigas, Bruno – sequence: 6 fullname: Hue, Louis – sequence: 7 fullname: Vanoverschelde, Jean-Louis |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/16489105$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc1u1DAUhS1URKcDT4CEvGKXIbbzZ3aloi2iCBZlbXmS64lbxw62MzCvwtPWmekPQoLN9eKe79x7fU7QkXUWEHpN8hUhJX0nb8YepI-rnNCKr2iel8_QInVoRkrGj9AiZxXLKsLKY3QSwk2eFHXFXqBjUhUNJ3m5QL9Pv3z7jGUb9VZG7Sz2EKJLBccecIh6mMyh4RTemKl1AfA0RnkLWFss7Vy3OnqHB9eBmWXahslomyUXHaK0EbfSd9oNO9fuYrLearm3_2NswkbvIiS3W21lGvLhJXqupAnw6v5dou_nH6_PLrOrrxefzk6vsrYoecygbbo1L6CWrKBcgWwVVYooydayUZR1tChlVdcAvGasa8qqLFhDgQPhFWeKLdHbg29a4MeUzheDDi0YIy24KYiqyWsyQ0v05l44rQfoxOj1IP1OPPxmEvCDoPUuBA9KtDru74teaiNILubkxENyYp-cmJNLLPuLfbT_L7U6UL3e9D-1BzH2u6CdcZvdE0A5EURcUsYT8P7fwPlkzDX8io_kEyjGTrE78ZbJBA |
CitedBy_id | crossref_primary_10_3390_foods10061266 crossref_primary_10_1242_jcs_041178 crossref_primary_10_1152_ajpheart_00329_2006 crossref_primary_10_1096_fj_201901440RR crossref_primary_10_1152_ajpheart_00664_2021 crossref_primary_10_1111_1744_7917_12795 crossref_primary_10_1152_ajpheart_00002_2007 crossref_primary_10_3390_antiox11040723 crossref_primary_10_1016_j_hermed_2019_100282 crossref_primary_10_2147_DDDT_S409373 crossref_primary_10_1155_2013_429207 crossref_primary_10_1007_s40256_018_0266_3 crossref_primary_10_2217_clp_09_43 crossref_primary_10_1038_s41392_025_02141_x crossref_primary_10_3389_fphar_2022_930308 crossref_primary_10_1002_jcb_30433 crossref_primary_10_1111_j_1365_2443_2011_01517_x crossref_primary_10_3390_ijms19102869 crossref_primary_10_1248_bpb_b17_01027 crossref_primary_10_1074_jbc_M802869200 crossref_primary_10_1152_ajpcell_00073_2014 crossref_primary_10_1152_ajpheart_00736_2019 crossref_primary_10_1016_j_mce_2012_03_013 crossref_primary_10_1016_j_biopha_2021_112538 crossref_primary_10_1111_jcmm_12220 crossref_primary_10_3390_biom11121834 crossref_primary_10_1002_ehf2_12937 crossref_primary_10_1016_j_numecd_2007_01_007 crossref_primary_10_1038_s41467_017_02795_4 crossref_primary_10_1016_j_yjmcc_2012_11_005 crossref_primary_10_1016_j_numecd_2017_04_009 crossref_primary_10_1007_s11897_012_0102_z crossref_primary_10_1016_j_bbadis_2014_10_016 crossref_primary_10_1016_j_bbadis_2013_02_015 crossref_primary_10_1016_j_mce_2019_110642 crossref_primary_10_1002_iub_1063 crossref_primary_10_1016_j_jep_2015_05_003 crossref_primary_10_1016_S1734_1140_11_70635_1 crossref_primary_10_1074_jbc_M112_363630 crossref_primary_10_1113_EP085091 crossref_primary_10_1007_s00424_020_02444_8 crossref_primary_10_1177_1559827612465576 crossref_primary_10_1210_en_2009_0624 crossref_primary_10_1152_ajpregu_90590_2008 crossref_primary_10_1016_j_plefa_2012_04_009 crossref_primary_10_1007_s00424_019_02285_0 crossref_primary_10_1152_ajpheart_00210_2014 crossref_primary_10_1161_RES_0000000000000097 crossref_primary_10_3109_10409238_2010_488215 crossref_primary_10_1152_ajpheart_00449_2022 crossref_primary_10_1016_j_bbalip_2016_04_008 crossref_primary_10_2337_db11_1132 crossref_primary_10_1016_j_biopha_2023_115271 crossref_primary_10_1007_s40256_022_00545_6 crossref_primary_10_1152_ajprenal_00034_2011 crossref_primary_10_1152_ajpendo_00160_2011 crossref_primary_10_1093_cvr_cvn093 crossref_primary_10_1016_j_bbamcr_2012_08_009 crossref_primary_10_1152_ajpendo_00158_2021 crossref_primary_10_1097_HCO_0b013e3282fcc2fa crossref_primary_10_3390_ph17070920 crossref_primary_10_1016_j_cmet_2014_09_018 crossref_primary_10_1080_21623945_2018_1525252 crossref_primary_10_1152_ajpheart_00738_2016 crossref_primary_10_1016_j_cbi_2022_110265 crossref_primary_10_1038_srep41166 crossref_primary_10_1093_cvr_cvt227 crossref_primary_10_3390_jcm10040721 crossref_primary_10_1007_s00360_013_0743_6 crossref_primary_10_1016_j_yjmcc_2012_12_015 crossref_primary_10_3390_cells10040905 crossref_primary_10_1016_j_diabres_2017_12_011 crossref_primary_10_12997_jla_2020_9_1_92 crossref_primary_10_1113_expphysiol_2006_034736 crossref_primary_10_1152_ajpheart_00058_2022 crossref_primary_10_1016_j_bbagen_2009_09_005 crossref_primary_10_1016_j_bbrc_2008_09_057 crossref_primary_10_1152_ajpheart_00873_2007 crossref_primary_10_1161_CIRCULATIONAHA_124_067876 crossref_primary_10_1152_ajpheart_00986_2010 crossref_primary_10_1016_j_numecd_2008_09_002 crossref_primary_10_1111_1755_5922_12482 crossref_primary_10_1152_ajpheart_01032_2005 crossref_primary_10_1093_cvr_cvr230 crossref_primary_10_1161_CIRCRESAHA_118_311371 crossref_primary_10_1161_JAHA_118_011640 crossref_primary_10_1038_nrd3431 crossref_primary_10_1161_CIRCRESAHA_113_302095 crossref_primary_10_1155_2016_2594703 crossref_primary_10_1016_j_ijcard_2008_04_010 crossref_primary_10_1111_ijd_16873 crossref_primary_10_1152_ajpheart_00965_2013 crossref_primary_10_1016_j_acvd_2020_06_006 crossref_primary_10_1016_j_febslet_2010_06_004 crossref_primary_10_1124_mol_108_050104 crossref_primary_10_1210_en_2007_1326 crossref_primary_10_1016_j_peptides_2010_04_009 crossref_primary_10_1152_ajpendo_00421_2009 crossref_primary_10_1016_j_apsb_2020_10_007 crossref_primary_10_1007_s00018_012_1198_8 crossref_primary_10_1161_CIRCHEARTFAILURE_108_821892 crossref_primary_10_1042_CS20080066 crossref_primary_10_1042_BSR20181995 crossref_primary_10_1152_ajpendo_00427_2011 crossref_primary_10_1042_BJ20120060 crossref_primary_10_1161_CIRCRESAHA_108_190918 crossref_primary_10_1016_j_bbalip_2016_03_014 crossref_primary_10_1111_jpi_12064 crossref_primary_10_1017_S0954422421000056 crossref_primary_10_1016_j_diabres_2019_107879 crossref_primary_10_1016_j_hfc_2012_06_002 crossref_primary_10_1021_acs_jafc_9b04274 |
Cites_doi | 10.1016/S0014-5793(01)02788-0 10.1161/01.RES.88.5.513 10.2337/diabetes.54.7.2179 10.1161/01.CIR.59.1.8 10.2337/diab.47.8.1281 10.1128/MCB.20.18.6704-6711.2000 10.1074/jbc.M503824200 10.1185/030079905X50606 10.1016/j.tcm.2005.04.005 10.2337/diab.46.3.524 10.1007/s001250051644 10.1056/NEJM199602293340906 10.1007/s00125-005-0016-3 10.1172/JCI10583 10.1152/ajpendo.00382.2002 10.1172/JCI6928 10.1111/j.1432-1033.1989.tb15186.x 10.1074/jbc.275.1.223 10.2337/diabetes.51.2.443 10.1046/j.1432-1327.1998.2580277.x 10.1128/MCB.26.1.63-76.2006 10.1016/j.cmet.2005.06.005 10.1242/jcs.01540 10.1016/j.biochi.2004.10.017 10.1042/bst0310213 10.1042/BJ20040885 10.1210/endo.131.3.1505458 10.1172/JCI200112348 10.1042/BST0330354 10.1074/jbc.M201494200 10.1152/ajpendo.00443.2005 10.2337/diabetes.49.4.647 10.1016/j.cub.2003.10.031 10.1042/bj20030048 10.1016/j.cmet.2005.05.009 10.1074/jbc.271.37.22289 10.2337/diabetes.51.8.2420 10.1074/jbc.M202489200 10.2337/diabetes.51.4.1110 10.2337/diabetes.54.8.2360 10.2337/diabetes.49.12.2063 10.1074/jbc.C100483200 10.1016/S0006-2952(02)01509-5 10.1016/S0960-9822(00)00742-9 10.1172/JCI13505 10.1152/ajpheart.1999.277.2.H643 10.1210/endo.136.2.7835271 10.2337/diabetes.53.12.3258 10.7326/0003-4819-131-4-199908170-00008 10.1074/jbc.274.43.30927 10.1038/sj.bjp.0704878 10.1016/j.lfs.2003.08.040 10.1042/BST0330346 10.2174/1566524053766103 10.1074/jbc.M506850200 10.2337/diabetes.54.3.803 10.1186/1475-4924-2-28 10.1074/jbc.272.12.7759 10.2337/diab.37.12.1595 10.2337/diabetes.52.5.1066 10.1042/bj1740603 10.1152/ajpheart.00374.2004 10.1016/S0140-6736(98)07037-8 |
ContentType | Journal Article |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1152/ajpheart.01269.2005 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | CrossRef MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Anatomy & Physiology |
EISSN | 1522-1539 |
EndPage | H250 |
ExternalDocumentID | 16489105 10_1152_ajpheart_01269_2005 ajpheart_291_1_H239 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | - 02 23M 2WC 39C 4.4 53G 5GY 5VS 8M5 ABFLS ABPTK ACIWK ACPRK ADACO ADBBV AENEX AFFNX AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL BKOMP C1A DIK DL E3Z EBS EJD F5P GX1 H13 KQ8 O0- OK1 P2P PQEST PQQKQ RAP RHF RHI RPL UKR WH7 WOQ --- 3O- 6J9 AAFWJ AAYXX ABJNI ACBEA BKKCC BTFSW CITATION EMOBN ITBOX RPRKH TR2 W8F XSW YSK YYP ~02 CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c459t-ec8db94e7a3429feacf2ff1fa3ba8f23d245a677ee9733d85654382e9e19693f3 |
ISSN | 0363-6135 |
IngestDate | Thu Jul 10 16:58:17 EDT 2025 Sat Sep 28 07:47:23 EDT 2024 Tue Jul 01 04:20:03 EDT 2025 Thu Apr 24 23:09:15 EDT 2025 Tue Jan 05 17:57:06 EST 2021 Mon May 06 11:36:58 EDT 2019 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c459t-ec8db94e7a3429feacf2ff1fa3ba8f23d245a677ee9733d85654382e9e19693f3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 16489105 |
PQID | 68071654 |
PQPubID | 23479 |
ParticipantIDs | pubmed_primary_16489105 crossref_primary_10_1152_ajpheart_01269_2005 highwire_physiology_ajpheart_291_1_H239 crossref_citationtrail_10_1152_ajpheart_01269_2005 proquest_miscellaneous_68071654 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2006-07-01 |
PublicationDateYYYYMMDD | 2006-07-01 |
PublicationDate_xml | – month: 07 year: 2006 text: 2006-07-01 day: 01 |
PublicationDecade | 2000 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | American journal of physiology. Heart and circulatory physiology |
PublicationTitleAlternate | Am J Physiol Heart Circ Physiol |
PublicationYear | 2006 |
References | R56A R61 R60 R63 R62 R21 R20 R64 R23 R22 R25 R24 R27 R26 R29 R28 R1 R2 R3 R4 R5 R7 R8 R9 R30 R32 R31 R34 R33 R36 R35 R38 R37 R39 R41 R40 R43 R42 R45 R44 R47 R46 R49 R48 R50 R52 R51 R10 R54 R53 R12 R56 R11 R55 R14 R58 R13 R57 R16 R15 R59 R18 R17 R19 |
References_xml | – ident: R5 doi: 10.1016/S0014-5793(01)02788-0 – ident: R4 doi: 10.1161/01.RES.88.5.513 – ident: R17 doi: 10.2337/diabetes.54.7.2179 – ident: R34 doi: 10.1161/01.CIR.59.1.8 – ident: R38 doi: 10.2337/diab.47.8.1281 – ident: R60 doi: 10.1128/MCB.20.18.6704-6711.2000 – ident: R32 doi: 10.1074/jbc.M503824200 – ident: R1 doi: 10.1185/030079905X50606 – ident: R63 doi: 10.1016/j.tcm.2005.04.005 – ident: R8 doi: 10.2337/diab.46.3.524 – ident: R14 doi: 10.1007/s001250051644 – ident: R2 doi: 10.1056/NEJM199602293340906 – ident: R43 doi: 10.1007/s00125-005-0016-3 – ident: R51 doi: 10.1172/JCI10583 – ident: R58 doi: 10.1152/ajpendo.00382.2002 – ident: R36 doi: 10.1172/JCI6928 – ident: R12 doi: 10.1111/j.1432-1033.1989.tb15186.x – ident: R19 doi: 10.1074/jbc.275.1.223 – ident: R35 doi: 10.2337/diabetes.51.2.443 – ident: R16 doi: 10.1046/j.1432-1327.1998.2580277.x – ident: R56 doi: 10.1128/MCB.26.1.63-76.2006 – ident: R61 doi: 10.1016/j.cmet.2005.06.005 – ident: R23 doi: 10.1242/jcs.01540 – ident: R11 doi: 10.1016/j.biochi.2004.10.017 – ident: R29 doi: 10.1042/bst0310213 – ident: R22 doi: 10.1042/BJ20040885 – ident: R30 doi: 10.1210/endo.131.3.1505458 – ident: R54 doi: 10.1172/JCI200112348 – ident: R9 doi: 10.1042/BST0330354 – ident: R45 doi: 10.1074/jbc.M201494200 – ident: R50 doi: 10.1152/ajpendo.00443.2005 – ident: R49 doi: 10.2337/diabetes.49.4.647 – ident: R62 doi: 10.1016/j.cub.2003.10.031 – ident: R57 – ident: R48 doi: 10.1042/bj20030048 – ident: R27 doi: 10.1016/j.cmet.2005.05.009 – ident: R42 doi: 10.1074/jbc.271.37.22289 – ident: R26 doi: 10.2337/diabetes.51.8.2420 – ident: R21 doi: 10.1074/jbc.M202489200 – ident: R52 doi: 10.2337/diabetes.51.4.1110 – ident: R55 doi: 10.2337/diabetes.54.8.2360 – ident: R31 doi: 10.2337/diabetes.49.12.2063 – ident: R33 doi: 10.1074/jbc.C100483200 – ident: R39 doi: 10.1016/S0006-2952(02)01509-5 – ident: R44 doi: 10.1016/S0960-9822(00)00742-9 – ident: R64 doi: 10.1172/JCI13505 – ident: R47 doi: 10.1152/ajpheart.1999.277.2.H643 – ident: R20 doi: 10.1210/endo.136.2.7835271 – ident: R13 doi: 10.2337/diabetes.53.12.3258 – ident: R15 doi: 10.7326/0003-4819-131-4-199908170-00008 – ident: R7 doi: 10.1074/jbc.274.43.30927 – ident: R40 doi: 10.1038/sj.bjp.0704878 – ident: R41 doi: 10.1016/j.lfs.2003.08.040 – ident: R59 doi: 10.1042/BST0330346 – ident: R3 doi: 10.2174/1566524053766103 – ident: R28 doi: 10.1074/jbc.M506850200 – ident: R18 doi: 10.2337/diabetes.54.3.803 – ident: R25 doi: 10.1186/1475-4924-2-28 – ident: R53 doi: 10.1074/jbc.272.12.7759 – ident: R46 doi: 10.2337/diab.37.12.1595 – ident: R37 doi: 10.2337/diabetes.52.5.1066 – ident: R10 doi: 10.1042/bj1740603 – ident: R24 doi: 10.1152/ajpheart.00374.2004 – ident: R56A doi: 10.1016/S0140-6736(98)07037-8 |
SSID | ssj0005763 |
Score | 2.243452 |
Snippet | 1 Division of Cardiology, School of Medicine, Université Catholique de Louvain; and 2 Hormone and Metabolic Research Unit, Université Catholique de Louvain and... Diabetic hearts are known to be more susceptible to ischemic disease. Biguanides, like metformin, are known antidiabetic drugs that lower blood glucose... |
SourceID | proquest pubmed crossref highwire |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | H239 |
SubjectTerms | AMP-Activated Protein Kinases Animals Biguanides - administration & dosage Cells, Cultured Dose-Response Relationship, Drug Drug Combinations Enzyme Activation Glucose - metabolism Insulin - administration & dosage Insulin Resistance - physiology Male Multienzyme Complexes - drug effects Multienzyme Complexes - metabolism Myocytes, Cardiac - metabolism Oligomycins - administration & dosage Protein-Serine-Threonine Kinases - drug effects Protein-Serine-Threonine Kinases - metabolism Proto-Oncogene Proteins c-akt - metabolism Rats Rats, Wistar |
Title | AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B |
URI | http://ajpheart.physiology.org/cgi/content/abstract/291/1/H239 https://www.ncbi.nlm.nih.gov/pubmed/16489105 https://www.proquest.com/docview/68071654 |
Volume | 291 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1522-1539 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0005763 issn: 0363-6135 databaseCode: KQ8 dateStart: 19971001 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVFQY databaseName: GFMER Free Medical Journals customDbUrl: eissn: 1522-1539 dateEnd: 20240930 omitProxy: true ssIdentifier: ssj0005763 issn: 0363-6135 databaseCode: GX1 dateStart: 19971001 isFulltext: true titleUrlDefault: http://www.gfmer.ch/Medical_journals/Free_medical.php providerName: Geneva Foundation for Medical Education and Research |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6FIiEuCFoeKa89IDiAQ_1YP44BAREQ1EMq5Wat7bUwJXbk2pXCT-GP8XeY2YftKCkCLlZk785amc-e2fHMN4Q8CzPHS8ESWF4uctigeMziKYus7IQlmZsyziVPwfyLPzvzPi7ZcjT6Nchaaptkkv7YW1fyP1qFc6BXrJL9B812QuEE_Ab9whE0DMe_0vF0fvpJsmGouOrLWraJQdKGr0gcW6x0by70CE1uertu-LlkCuEyyfGyaOpKNcRR9BEyN90CKehZlg1yV2dFtdpU6QZjtJcFl-IHy2LSNNI9gLTzogSzqFs5G3Jb81FowFIhAyoyoj_BSqha5bmnRY1psfK7fz-iixiIuql1HubnNu0yh4qy0I2x26wWg-G8xWbG2xQKfew30dVKusSnFjr5eRACCUwIxJR-ubAHVrwn5rXuRPYOftVLeuYo_qRd68GQjZZ_W2Mz8WYCttuXtUxsOBogsF5JQMFOMwRvi_WmtEtwNJeuketO4PvYWuPDcpB7FKgWf-a-NR0WrP96z-pIbKvlbXtPhtH66t2R9JIWt8ktvb2hU4XVO2QkykNyNC1Bp6sNfU5PO60ekhtznddxRH4ikmkPKWqQTAFqdIBkWuVUI5kqJNOipLzEo0QylUjGYTtIpttIhvFcih8sC9M0kqlCMn1zl5y9f7d4O7N01xAr9VjUWCINsyTyRMBd8LVycCxyJ8_tnLsJD3PHhZcT434QCBEFrpuFDKurQ0dEApmi3Ny9Rw7KqhQPCMVch8wLE-57kYfEk8KxE7BYke36J8JmY-IYbcSpptTHzi7fY7m1Zk5stBlLbWLPV5j0qpu0Vowyfx7uGjXH_ZMXY4BqAZjrpgDcYztGaMfrLB-TF_tmdfL70WPy1GAnBsuCnwt5Kar2IvZD2H7AnzMm9xWk-tvVaDy-8spDcrN_UB-Rg6ZuxWPw3pvkiXwSfgOsWvra |
linkProvider | Geneva Foundation for Medical Education and Research |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=AMPK+activation+restores+the+stimulation+of+glucose+uptake+in+an+in+vitro+model+of+insulin-resistant+cardiomyocytes+via+the+activation+of+protein+kinase+B&rft.jtitle=American+journal+of+physiology.+Heart+and+circulatory+physiology&rft.au=Bertrand%2C+Luc&rft.au=Ginion%2C+Audrey&rft.au=Beauloye%2C+Christophe&rft.au=Hebert%2C+Alexandre+D&rft.date=2006-07-01&rft.issn=0363-6135&rft.volume=291&rft.issue=1&rft.spage=H239&rft_id=info:doi/10.1152%2Fajpheart.01269.2005&rft_id=info%3Apmid%2F16489105&rft.externalDocID=16489105 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0363-6135&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0363-6135&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0363-6135&client=summon |